Lineage Cell Therapeutics (LCTX) announced the receipt of an induced pluripotent stem cell line containing hypoimmunity edits, from Factor ...
Lung-on-chip model made of cells derived from a single person furthers understanding of tuberculosis and potential ...
About Fate Therapeutics, Inc. Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to bringing a pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies ...
DALLAS--(BUSINESS WIRE)--Colossal Biosciences (“Colossal”), the world’s first de-extinction company, announces today that their Woolly Mammoth team has achieved a global-first iPSC (induced ...
From the beginning, stem cell research has presented hope for patients living with a range of diseases, from cancer to type 1 diabetes to Parkinson’s disease. The limiting factor has been the ...
The "Induced Pluripotent Stem Cells Market Report by Derived Cell Type, Application, End User, Countries and Company Analysis, 2025-2033" has been added to ResearchAndMarkets.com's offering. The ...
It's been more than 10 years since Japanese researchers Shinya Yamanaka, M.D., Ph.D., and his graduate student Kazutoshi Takahashi, Ph.D., developed the breakthrough technique to return any adult cell ...
The iPS cells passed the standard barrage of tests for pluripotency, and microarray analyses demonstrated that these cells exhibited similar gene expression profiles to embryonic stem cells. The new ...
Cellular immunotherapy—for example, Chimeric Antigen Receptor (CAR)-T cell therapy—has shown great efficacy in treating various hematologic malignancies. CAR-T therapy has undergone notable changes, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback